New drug AB821 enters first human tests for tough cancers
NCT ID NCT07027488
First seen Mar 18, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called AB821 in people with advanced melanoma or other solid tumors that respond to immunotherapy. The main goal is to check safety and find the right dose. About 50 adults will receive the drug every two weeks at Yale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.